XML 57 R44.htm IDEA: XBRL DOCUMENT
v3.25.3

Schedule of Contractual Clinical Trials (Details) | 9 Months Ended
--- | ---
Sep. 30, 2025 USD ($) Integer
Other Commitments [Line Items] |  |
Remaining financial contractual commitment | $ 292,000 |
Phase 1b 2 [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2) |
Estimated Start Date | January 2024 |
Estimated End Date | December 2027 |
Number of Patients in Trial | Integer | 21 |
Expected Date | December 2026 |
Remaining financial contractual commitment | $ 0 | [1]
Phase 1b [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b) |
Estimated Start Date | August 2024 |
Estimated End Date | December 2026 |
Number of Patients in Trial | Integer | 37 |
Expected Date | June 2026 |
Remaining financial contractual commitment | $ 0 | [1]
Phase 1b Two [Member] |  |
Other Commitments [Line Items] |  |
Clinical trial, description | LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b) |
Estimated Start Date | June 2023 |
Number of Patients in Trial | Integer | 14 |
Expected Date | December 2025 |
Remaining financial contractual commitment | $ 292,000 |
[1] | The Company has no financial contractual commitments associated with these clinical trials at September 30, 2025.

X
- Definition Clinical trial description. + References No definition available. + Details
Name: | LIXT_ClinicalTrialDescription
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual clinical trial period end date + References No definition available. + Details
Name: | LIXT_ContractualClinicalTrialPeriodEndDate
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual clinical trial period start date. + References No definition available. + Details
Name: | LIXT_ContractualClinicalTrialPeriodStartDate
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected date of preliminary efficacy signal. + References No definition available. + Details
Name: | LIXT_ExpectedDateOfPreliminaryEfficacySignal
Namespace Prefix: | LIXT_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of patient in trial. + References No definition available. + Details
Name: | LIXT_NumberOfPatientInTrial
Namespace Prefix: | LIXT_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhaseMD1b2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OtherCommitmentsAxis=LIXT_ClinicalTrialPhase1bTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |